NeuromarkR™ Platform
Our technology provides clinicians and patients with tools to objectively detect triggers for relapse such as craving or distress at the point of care.
Why NeuromarkR™?
Including objective neurofeedback:
Decrease recurrent drug use by over 25%
Improve treatment retention by over 30%
200%-300% improved measurement reliability
Reduce health costs by tens of thousands
Why Address Triggers?
Triggers jeopardize recovery for the vast majority of people with Substance Use Disorder (SUD), leading to distress, craving, and recurrent substance use even years after initial treatment.
Improving Outcomes through Awareness
Understanding one’s triggers can improve abstinence rates by 30-70%. However, many are unaware of their triggers, making this awareness challenging to achieve.
Innovative Trigger Management
Noninvasive sensors can measure brain and body responses to triggers, providing valuable insights even if the patient or clinician is unaware. Neurotype Inc. adapts this science for clinical use to enhance trigger awareness and treatment outcomes.
Objective Measurement
NeuromarkR™ uses noninvasive EEG sensors to measure Visual Evoked Potentials (VEPs) in a 6-minute scan, quantifying the brain’s response to triggers. This tracks changes over time, providing objective data before, during, and after therapy.
Treatment Companion
NeuromarkR™ generates standardized reports for clinicians, assessing therapy effectiveness and recommending additional treatments when needed.
Targeted Therapies
We develop VEP-based neurofeedback therapies to help patients overcome specific triggers, complementing psychological, pharmacological, and neuromodulation therapies.
Transparent and Evidence-Based
NeuromarkR™ allows data export for further analysis, supporting transparent, evidence-based care and informed treatment decisions.
Why Neurotype Inc.?
Our PhD-level team has over 30 years of research experience with NeuromarkR™ technologies, dedicated to providing advanced tools for managing craving and addiction triggers.
